Merck Aktie
WKN DE: A0YD8Q / ISIN: US58933Y1055
|
04.02.2025 12:47:39
|
Merck Stock Down 8% On Weak FY25 Outlook - Update
(RTTNews) - While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and sales guidance for the full-year 2025, well below analysts' estimates.
For fiscal 2025, Merck now projects adjusted earnings in a range of $8.88 to $9.03 per share on sales between $64.1 billion and $65.6 billion.
On average, analysts polled expect the company to report earnings of $9.21 per share on sales of $67.36 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Merck Co.
|
20:04 |
Dow Jones-Handel aktuell: So entwickelt sich der Dow Jones aktuell (finanzen.at) | |
|
18:01 |
Schwacher Handel in New York: Dow Jones leichter (finanzen.at) | |
|
16:02 |
Freundlicher Handel in New York: Dow Jones zum Handelsstart im Plus (finanzen.at) | |
|
25.02.26 |
Optimismus in New York: Dow Jones beendet den Handel im Plus (finanzen.at) | |
|
24.02.26 |
Dienstagshandel in New York: Dow Jones legt zum Handelsstart zu (finanzen.at) | |
|
23.02.26 |
Verluste in New York: Dow Jones beendet den Montagshandel in der Verlustzone (finanzen.at) | |
|
23.02.26 |
Merck & Co.-Aktie gewinnt: Pharmasparte vor Umbau (dpa-AFX) | |
|
23.02.26 |
Merck splits operations to separate oncology from non-cancer drugs (Financial Times) |
Analysen zu Merck Co.
Aktien in diesem Artikel
| Merck Co. | 101,40 | -2,31% |
|